🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Alirocumab

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 2 small molecule on hold

    1 trial

  2. Alirocumab and Cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 other active

    1 trial

  3. Alisertib

    Takeda

    Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  4. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  6. Alisertib

    PUMA BIOTECHNOLOGY, INC.

    Hormone Receptor Positive HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  8. Almonertinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Non-small Cell Stage IV

    phase 2 small molecule active

    1 trial

  10. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. Almonertinib

    The First People's Hospital of Lianyungang

    EGFR Positive Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Alpelisib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  13. Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  14. Amcenestrant

    Sanofi Pasteur

    Breast Cancer Metastatic

    phase 2 small molecule terminated

    1 trial

  15. Ametinib combined with bevacizumab

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  17. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  18. Anlotinib

    The First People's Hospital of Lianyungang

    Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. Anlotinib combined Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. Anlotinib plus Pemetrexed

    Henan Provincial People's Hospital

    Non-squamous Cell Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Anti-HER2 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 mab terminated

    1 trial

  22. Apatinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  23. Apatinib

    The First People's Hospital of Lianyungang

    Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Apatinib

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources